Prime MedicinePRME -5.56%23 EV-to-EBITDA is -3.13 as of Jul. 13, 2026. GuruFocus rates PRME with a GF Score™ of 23/100. The stock has 5 warning signs investors should review. Among 391 Biotechnology companies, Prime Medicine ranks worse than 255754.22% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Prime Medicine's enterprise value is $623.82 Mil.
Prime Medicine's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-199.14 Mil. Therefore, Prime Medicine's EV-to-EBITDA for today is -3.13.
The historical rank and industry rank for Prime Medicine's EV-to-EBITDA or its related term are showing as below:
PRME'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.67 Med: -2.36 Max: -0.43
Current: -3.13
During the past 6 years, the highest EV-to-EBITDA of Prime Medicine was -0.43. The lowest was -4.67. And the median was -2.36.
PRME's EV-to-EBITDA is ranked worse than 100% of 391
companies
in the Biotechnology industry
Industry Median: 13.02
vs PRME: -3.13
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Prime Medicine (NAS:PRME) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prime Medicine's PE Ratio (TTM) for today is calculated as:
Prime Medicine's share price for today is $3.57.
Prime Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.250.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Prime Medicine's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Prime Medicine's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prime Medicine EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prime Medicine's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Prime Medicine's EV-to-EBITDA falls into.
Prime Medicine's current Enterprise Value is $623.82 Mil.
Prime Medicine's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-199.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prime Medicine (PRME) has a EV-to-EBITDA of -3.13 as of Jul. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Prime Medicine. According to the industry distribution chart, Prime Medicine ranks #999999 out of 391 companies in the Biotechnology industry.
Is Prime Medicine's EV-to-EBITDA too high?
Prime Medicine's current EV-to-EBITDA is -3.13. Based on the distribution chart, Prime Medicine ranks #999999 out of 391 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Prime Medicine has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's EV-to-EBITDA compare to EIKN and CRMD?
According to the Biotechnology industry distribution chart, Prime Medicine ranks #999999 out of 391 companies for EV-to-EBITDA. This places Prime Medicine in the lower half of its industry. The industry median EV-to-EBITDA is 13.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.02, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Prime Medicine. For the Biotechnology industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prime Medicine's current EV-to-EBITDA is -3.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current EV-to-EBITDA of -3.13. The current EV-to-EBITDA is -3.13. Prime Medicine's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Prime Medicine (PRME), the current EV-to-EBITDA is -3.13 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
23GF Score
Get the complete analysis for PRME
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRME has been successfully added to your 
